The work of Stijn van Roessel, a Hepato-Pancreato-Biliary researcher of Cancer Center Amsterdam, and co-workers about pancreatic cancer treatment was published in JAMA Oncology.
This collaborative study included 520 patients from 31 centers in 19 countries who had neoadjuvant FOLFIRINOX chemotherapy followed by resection of pancreatic cancer. In these patients, postoperative (adjuvant) chemotherapy did not improve survival (29 vs 29 months survival). Postoperative chemotherapy was only associated with improved survival in patients with positive lymph nodes on final pathology (26 vs 13 months survival). This is a novel finding in treating pancreatic cancer. These findings will need confirmation in a randomized trial but are expected to lead to a more personalized use of chemotherapy after surgery.
You can read the article here: